Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Investigate the Efficacy, Safety and Tolerability of Oral Administered AK0901 Capsules in Children Aged 6-12 Years Old With Attention Deficit Hyperactivity Disorder

NCT06359899 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06359899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06359899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Investigate the Efficacy, Safety and Tolerability of Oral Administered AK0901 Capsules in Children Aged 6-12 Years Old With Attention Deficit Hyperactivity Disorder
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 28, 2024
Completion date
January 11, 2025
Enrollment
55 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adhd